Furthermore, L-BORT exposure significantly blocked BCR/ABL kinase activities and sensitized CML cell lines, tumor cells and doxorubicin (DOX) resistant cells to DOX. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.